Drugs / Pirenzepine
Pirenzepine
also known as
WST-057 · 350320 · 9110700 · ACI-91 · Gastri p · Gastrozepin · LS 519 C12 · LS 519 CL2 · +5 more
Small molecule targets CHRM1 via inhibition
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT05488873 | Nov 2022 → Apr 2026 overdue | chemotherapy-induced neuropathy | WinSanTor, Inc | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05005078 | Feb 2022 → Jan 2023 | peripheral neuropathy | WinSanTor, Inc | Completed | No outcome recorded |
| Phase 2 | NCT04786340 | Nov 2020 → Dec 2022 | diabetes mellitus, diabetic polyneuropathy | WinSanTor, Inc | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04005287 Comparator | Oct 2019 → Dec 2021 | diabetic polyneuropathy | WinSanTor, Inc | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2013-01-31 | AC Immune SA | AC Immune to discontinue development of ACI-91 small molecule acimmune.com ↗ |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pirenzepine | “A 16-Week Phase 2a Study of Topical Pirenzepine (WST-057) or Placebo to Treat HIV-Associated Distal Sensory Polyneuropathy (DSP) in Patients With HIV (PWH)” NCT05005078 ↗ |
| Known as | 350320 | ChEMBL registry synonym — accepted as the source's own label CHEMBL9967 ↗ |
| Known as | 9110700 | ChEMBL registry synonym — accepted as the source's own label CHEMBL9967 ↗ |
| Known as | ACI-91 | ChEMBL registry synonym — accepted as the source's own label CHEMBL9967 ↗ |
| Known as | Gastri p | ChEMBL registry synonym — accepted as the source's own label CHEMBL9967 ↗ |
| Known as | Gastrozepin | ChEMBL registry synonym — accepted as the source's own label CHEMBL9967 ↗ |
| Known as | LS 519 C12 | ChEMBL registry synonym — accepted as the source's own label CHEMBL9967 ↗ |
| Known as | LS 519 CL2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL9967 ↗ |
| Known as | NSC-757846 | ChEMBL registry synonym — accepted as the source's own label CHEMBL9967 ↗ |
| Known as | Pirenzepina | ChEMBL registry synonym — accepted as the source's own label CHEMBL9967 ↗ |
| Known as | Pirenzepine dihydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL9967 ↗ |
| Known as | Pirenzepine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL9967 ↗ |
| Known as | PIRENZEPINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL9967 ↗ |
| Known as | WST-057 | “A 16-Week Phase 2a Study of Topical Pirenzepine (WST-057) or Placebo to Treat HIV-Associated Distal Sensory Polyneuropathy (DSP) in Patients With HIV (PWH)” NCT05005078 ↗ |
| Action | Inhibit | “Muscarinic acetylcholine receptor M1 antagonist” CHEMBL9967 ↗ |
| Modality | Small molecule | — CHEMBL9967 ↗ |
| Route | Topical | “The WST-057 is the active topical solution and contains pirenzepine free base monohydrate.” NCT04786340 ↗ |
| Target | CHRM1 | “Muscarinic acetylcholine receptor M1 antagonist” CHEMBL9967 ↗ |